Question 1

What is Alamar Biosciences?

Accepted Answer

Alamar Biosciences is a Entity.

Question 2

How often does Alamar Biosciences appear in global news?

Accepted Answer

Tracked across 5 news events drawn from 41 articles.

Question 3

When was Alamar Biosciences first tracked by Ergen?

Accepted Answer

First tracked on Apr 17, 2026.

Question 4

When was Alamar Biosciences last mentioned in news?

Accepted Answer

Last active on Aug 06, 2026.

Question 5

What is Alamar Biosciences's current news sentiment?

Accepted Answer

Aggregate sentiment score: 51 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Alamar Biosciences in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 5 events.

Question 7

What is the most recent event involving Alamar Biosciences?

Accepted Answer

Alamar Biosciences Lists on NASDAQ (Apr 20, 2026, 6 articles).

Question 8

How did the "Alamar Biosciences Lists on NASDAQ" event impact Alamar Biosciences?

Accepted Answer

Alamar Biosciences successfully listed on the Nasdaq-100 Stock Exchange, raising its market capitalization to approximately $1.5 billion and enabling further development of its proteomics technologies.

Question 9

How did the "Alamar Biosciences launches NULISA DBS Kit" event impact Alamar Biosciences?

Accepted Answer

Alamar Biosciences launched its NULISA DBS Extraction Kit, which is expected to expand the accessibility and application of its proteomics technology, potentially increasing its market share and revenue.

Question 10

How did the "Alamar NULISA at AAIC 2026" event impact Alamar Biosciences?

Accepted Answer

Alamar is the central company; its NULISA platform is featured in over 140 presentations, highlighting growing adoption and potential for future revenue.

Question 11

How did the "Alamar launches national Alzheimer's proteomics initiative" event impact Alamar Biosciences?

Accepted Answer

Alamar is the lead company providing its NULISAseq Neuro 220 panel and driving the initiative, enhancing its reputation and potential market reach.

Question 12

How did the "Alamar launches NULISAseq Immune 340 Panel" event impact Alamar Biosciences?

Accepted Answer

Alamar launched the NULISAseq Immune 340 Panel, expanding its product line and reinforcing its leadership in precision proteomics. This could drive future revenue growth and enhance its competitive position.

Question 13

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.